UroGen Pharma (NASDAQ: URGN) — Perfil da empresa, notícias e dados financeiros
UroGen Pharma develops therapies for urological diseases, aiming to improve patients' lives with advanced treatment options.
UroGen Pharma
UroGen Pharma (NASDAQ:URGN) is a specialized biopharmaceutical company focused on developing and commercializing innovative therapies for urological pathologies. The company's main objective is to improve patients' lives by offering new and advanced treatment options for urothelial and urinary tract cancers, among other diseases. UroGen's proprietary technology, RTGel, underpins several of its development projects, aiming to enhance the delivery and efficacy of therapeutics directly to the urinary tract. With a commitment to innovation, UroGen Pharma works on a broad range of projects, from research and development to the commercialization of its products, targeting conditions that have long been underserved by the medical community. The firm is dedicated to pushing the boundaries of urological care, striving to provide breakthrough solutions that can significantly impact patient outcomes.
Resumo
Operações
Produtos e/ou serviços de UroGen Pharma
- Jelmyto (mitomycin) for pyelocalyceal solution, a treatment for adults with low-grade upper tract urothelial cancer.
- UGN-102 (mitomycin) for intravesical solution, aimed at treating low-grade non-muscle invasive bladder cancer, currently under clinical development.
- RTGel technology platform, a proprietary reverse-thermal hydrogel technology designed for sustained release of therapeutic agents directly to the urinary tract.
- BotuGel, in early research stages, explores the application of RTGel with botulinum toxin for various urological conditions.
- Research collaboration on the use of RTGel technology for gene therapy in urological diseases, focusing on non-viral delivery systems.
- Development of innovative formulations and delivery systems for existing drugs to improve efficacy, safety, and patient compliance in urological care.
equipe executiva do UroGen Pharma
- Elizabeth A. BarrettPresident, CEO & Director
- Jason Drew SmithGeneral Counsel, Chief Compliance Officer & Corporate Secretary
- Mark P. SchoenbergChief Medical Officer
- Christopher DegnanChief Financial Officer
- Vincent I. PerroneSenior Director of Investor Relations
- Alison HardgroveSenior Vice President of Human Resources
- Marina KonortyExecutive Vice President of Research & Development and Technical Operations
- James OttingerExecutive Vice President of Regulatory Affairs & Quality
- Michael J. LouieChief Development Officer
- Timothy SimonSenior Vice President of Business Development & Portfolio Strategy
Últimas notícias sobre a UroGen Pharma
Principais indicadores financeiros
Resultados divulgados pela UroGen Pharma, em USD.
- Cap. de mercado
- 1,7 bi
- Receita (TTM)
- 188,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.0
- Dividend yield
- —
- Margem de lucro
- -51.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 109,8 mi | -124,9 mi | -153,5 mi | |
| 90,4 mi | -96,8 mi | -126,9 mi | |
| 82,7 mi | -65,5 mi | -102,2 mi | |
| 64,4 mi | -79 mi | -109,8 mi |